@IBCG family 20th anniversary in Modena. Celebrating the past, preparing the future!! ⁦@BladderCa⁩ ⁦@BladderCancerUK⁩ ⁦@WorldBladderCan⁩ ⁦@FPuigvert⁩ upfront bladder cancer clinical research!

Looking forward to today’s bladder and kidney cancer oral sessions at #ASCO26. Congratulations to all the presenters! Especially excited to see @tompowles1 present the 3.5-year FU from EV-302 with subsequent Tx & outcomes that will help inform real-world patient care. Looking forward to the discussion by @apolo_andrea on the rapidly evolving era of nectin-4 ADCs shaping bladderca care. 📍Arie Crown Theatre] 🕒 [2.45-5.45 PM CST @uromigosjapan @Uromigos @TresUramigas @brian_rini @ASCOPost @CleClinicMD @OncoAlert @OncBrothers @urotoday @GUOncologyNow

Happening now! @UroDocAsh kicking off @IBCG_BladderCA @AmerUrological Bladderca Forum Debates to address the tough topics facing us in clinic globally. @spsutkaMD @AndreaNecchi @UrogerliMD @SimaPorten @pjhensley11 @BladderCancerUS @JosephBBlack @JanetKukreja @SBoorjian @marigfern

Not a lecture. Not a debate. Just three GU oncologists saying what they actually think about the data. Genuinely thrilled to sit down with @GUOncologyNow, @PGrivasMDPhD, and @CParkMD at #OncForum2026 in Chicago on May 31. People I genuinely respect and who will not hold back. Register 👇 bit.ly/4sEtXG5 #GUOncology #OncForum2026 #bladderCa #RCC #prostateca

Honored to participate in the @AmerUrological Bladderca Plenary Crossfire controversies #AUA26 to make a case for saving the bladder after next-gen neoadjuvant therapies! Come join us for an exciting session moderated by @UroDocAsh raising the bar for the arguments! @AmyLuckenbaugh @ARRODRIGUEZMD #JohnGore 👇

Career, family, and mentorship - what matters most for women in urology? AUANews spoke with @MeghanACooperDO on navigating it all. 🩺 Beyond the Clinic 🔗 bit.ly/3QpoTrX 👤 mayocl.in/4txqKcU #SNM #bladderca #BPH @MayoClinic @AmerUrological @SiobhanHartigan

Novel therapies, clinical pearls and best practices at #CBCF26 all meeting highlights posted soon on uropedia.org @pcvblack @Nimira_A @GSK_UofT @BladderCa

#CBCF26 experts in bladder cancer joining forces for education and research. @pcvblack @Nimira_A @GSK_UofT @BladderCa

#ASCOGU26 Day 2 Bladderca A lot of exciting practice changing/informing trials & exceptional science 👉KN B15 @MattGalsky perioperative EV-P bs Gem Cis in MIBC. Unprecedented pCR 57% EFS HR 0.53 NR vs 48.5 mos. Qs around optimal duration of Tx remain. 👉SunRise 2 @AndreaNecchi gem IDRS bs CRT, did not improve BI EFS. Trial stopped early. CRT remains SOC 👉 ImVigor011 exploratory analysis of ctDNA dynamics @tompowles1 @OncoBellmunt clearance/dynamics of ctDNA on adjuavnt atezo associated with better DFS 👉FIH trial of FX909, a small molecule inverse agonist PPAR gamma in mUC shows efficacy. @MattGalsky @Uromigos @OncoAlert

Excited to share our scoping review on computational pathology in bladder cancer in @BladderCa. 💯 hard work done by our spectacular @UNCDeptMedicine @UNCHemeOnc fellow @MSuperdock journals.sagepub.com/doi/10.…

Not true. RC and a thorough PLND cures about 1/3 of node bladderCA pts with surgery ALONE. S1011 enrolled relatively low risk pts (their control performed 10% better than designed) and expected an unrealistically large benefit from the ePLND (10% ⬆️3 yr RFS)=poor design.

Excited to be at @AUC3_Official consensus meeting #Kidneyca #Bladderca led by @DrChoueiri @DrRanaMcKay @montypal @DrRosenbergMSK @OncoAlert

@AndreaNecchi does a phenomenal job highlighting the explosive growth in bladderca treatment & biomarker landscape with cDNA He is a trailblazer leading the way with next gen IITs @SanRaffaeleMI #GURetreat25 @BrigidaMaiorano

Elegant overview of BCG & IO advances in bladderca by @UroDocAsh at @SanRaffaeleMI urologic retreat 4th edition #GUReRetreat25 BCG is still the undisputed king in NMIBC. We need to think about pros & cons of adding IO to BCG upfront. @AndreaNecchi @IBCG_BladderCA

Thanks for your insights! Was such a fun and exciting discussion about the rapidly changing landscape in bladderca.

Off on a short visit to Edinburgh for #SIU2025Edinburgh @SIU_urology to speak about adj RT in #bladderca. 🤔 Can I change the title to “zap zap after making a poor choice” and conclude with “just leave it inside”? #whydyatakeitout #tongueincheek @achoud72 @AlisonBirtle

Agree with @montypal 💯💯 @tompowles1 has led the recent advancements in Bladder and Kidney cancer and cancer in general! now paving the way forward with providing us the most promising biomarker in bladderca to date-ctDNA! Kudos to him learning from exploratory negative ph 3 trial (IMvigor010) and launching a prospective ph 3 RCT (IMbigor012) which is the 1st trial in this space to guide us how we can avoid overtreatment in adjuvant setting! @Uromigos @DrChoueiri @neerajaiims @PGrivasMDPhD

Tremendous presentation by @tompowles1 #ESMO25 @myESMO on IMvigor011 born from the most imp neg trial IMvigor010 in bladderca. Practice changing data for the 1st time using ctDNA for tx intervention in adjuvant setting in MIBC. @DrChoueiri @MyriamChalabi @montypal @Uromigos

Love that KEYNOTE905/EV303 results positive and suggests possible brighter future for #bladderca. But need to keep check on over-enthusiasm. ⚠️Median FU only 25.6mths ⚠️pCR 57.1% lovely, but at cost of 71.3% G3 TRAEs Lots of potential, but let’s calm down…

Congrats on creating @IBCG_BladderCA footprint for Mexican bladderca guidelines!